{"entity":{"id":"nct05951608","kind":"trial","name":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AK127 in combination with AK112 in advanced solid tumours, run by Akeso, active and no longer recruiting.","summary":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05951608 by Akeso, with 216 participants enrolled, started 2023-10-16 and due to reach its primary completion in 2026-05-01. Interventions recorded: AK127 in combination with AK112.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05951608","url":"https://clinicaltrials.gov/study/NCT05951608"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05951608","phase":"1/2","setting":"A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK112 in Patients With Advanced Malignant Tumors","sponsor":"Akeso","enrolled":216,"outcomes":[]},"route":"/trials/nct05951608/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}